<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182856</url>
  </required_header>
  <id_info>
    <org_study_id>1012.39</org_study_id>
    <nct_id>NCT02182856</nct_id>
  </id_info>
  <brief_title>Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD</brief_title>
  <official_title>A Randomised, Double-blind, Active-controlled, Within-patient Trial Comparing the Effect of Single Doses of Nebulised Ipratropium 500µg, Salbutamol Sulphate 3mg, Salbutamol 6mg and the Combination Therapy Salbutamol Sulphate 3 mg Plus Ipratropium 500µg on Arterial Oxygen Saturation in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to compare the effects of nebulised salbutamol or ipratropium alone in patients with&#xD;
      COPD with those of combined salbutamol and ipratropium nebuliser solution on arterial oxygen&#xD;
      saturation (SaO2) and to characterise patients with COPD (chronic obstructive pulmonary&#xD;
      disease) at risk of significant arterial oxygen desaturation following nebulised salbutamol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of arterial oxygen saturation (SaO2)</measure>
    <time_frame>over 70 min observation period from each start of nebulisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in the first second of expiration (FEV1)</measure>
    <time_frame>up to 60 min after end of nebulisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relaxed (expiratory) vital capacity (VC)</measure>
    <time_frame>up to 60 min after end of nebulisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced (expiratory) vital capacity (FVC)</measure>
    <time_frame>up to 60 min after end of nebulisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory ratio (FER)</measure>
    <time_frame>up to 60 min after end of nebulisation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Ipratropium bromide/salbutamol sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomised sequence of four different treatments&#xD;
Ipratropium bromide 500 µg/salbutamol sulphate 3 mg&#xD;
Ipratropium 500 µg&#xD;
Salbutamol sulphate 3 mg&#xD;
Salbutamol sulphate 6 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium bromide 500 µg/salbutamol sulphate 3 mg</intervention_name>
    <arm_group_label>Ipratropium bromide/salbutamol sulphate</arm_group_label>
    <other_name>Combivent® UDVs®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium 500 µg</intervention_name>
    <arm_group_label>Ipratropium bromide/salbutamol sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol sulphate 3 mg</intervention_name>
    <arm_group_label>Ipratropium bromide/salbutamol sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol sulphate 6 mg</intervention_name>
    <arm_group_label>Ipratropium bromide/salbutamol sulphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients with moderate to severe stable COPD:&#xD;
&#xD;
               -  Patients with a diagnosis of chronic bronchitis and/or emphysema&#xD;
&#xD;
               -  FEV1 &lt;65% of predicted value without regard to prior treatment&#xD;
&#xD;
               -  Forced expiratory ration (FER = FEV1/VC) &lt;70% of predicted value without regard&#xD;
                  to prior treatment&#xD;
&#xD;
               -  Patients must not have had a respiratory infection or an exacerbation of COPD&#xD;
                  during the four weeks immediately prior to entering the trial&#xD;
&#xD;
               -  Patients must not have changed their normal treatment for COPD during the four&#xD;
                  weeks immediately prior to entering the trial&#xD;
&#xD;
          -  Patient aged ≥40 years&#xD;
&#xD;
          -  Patients with a smoking history of ≥15 pack-years&#xD;
&#xD;
          -  Patients must have given informed consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of asthma, bronchiectasis, cystic fibrosis or bronchiolitis&#xD;
             obliterans&#xD;
&#xD;
          -  Patients with any of the following:&#xD;
&#xD;
               -  untreated angle closure glaucoma&#xD;
&#xD;
               -  hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
               -  tachyarrhythmia&#xD;
&#xD;
               -  recent myocardial infarction (within six months of screening visit)&#xD;
&#xD;
               -  severe organic cardiac or vascular disorder&#xD;
&#xD;
               -  untreated hyperthyroidism&#xD;
&#xD;
               -  diabetes mellitus (after approval of Protocol Amendment 1, the inclusion of well&#xD;
                  controlled diabetic patients was allowed)&#xD;
&#xD;
          -  Patients who are pregnant, or who are planning a pregnancy, and nursing mothers&#xD;
&#xD;
          -  Patients known to be hypersensitive to anticholinergic drugs or to β2 agonists&#xD;
&#xD;
          -  Patients known to abuse drugs or alcohol&#xD;
&#xD;
          -  Patients, who in the opinion of the investigator, are likely not to co-operate with&#xD;
             any of the requirements of the trial&#xD;
&#xD;
          -  Patients with a PaO2 (arterial carbon dioxide tension) &lt;56 mmHg (7.5 kPa) at rest&#xD;
             while breathing air without regard to prior treatment&#xD;
&#xD;
          -  Patients with a SaO2 ≤85% at rest while breathing air without regard to prior&#xD;
             treatment&#xD;
&#xD;
          -  Patients who are taking part in another investigation, and patients who have&#xD;
             participated in another clinical trial during the three months immediately preceding&#xD;
             entry to this trial&#xD;
&#xD;
          -  Patients on home oxygen concentrator therapy&#xD;
&#xD;
          -  Patients who have previously participated in the randomised phase of this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1012/1012.39_U01-1283.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

